Nº 02/2009 |
2018 |
Raloxifene |
LFM |
Blanver Farmoquímica e Farmacêutica S.A, Nortec Química S.A. |
2009 |
Lack of perspective for medicine centralization. |
Nº 03/2009 |
2018 |
Formoterol + Budesonide |
Farmanguinhos |
Chemo Iberica S.A. Nortec Química S.A. |
2009 |
Absence of a centralization perspective, and the fact that the partnership does not present evolution. |
Nº 04/2012 |
2017 |
Lopinavir + Ritonavir |
FURP, Farmanguinhos, IQUEGO |
Cristália Produtos Químicos Farmacêuticos Ltda. |
2012 |
Medicine does not meet the definition of 'strategic for SUS, and national production is no longer relevant for the Industrial Health Complex due to the reduction of demand for the financial area' (Health Surveillance Secretariat). |
Nº 06/2012 |
2014 |
Budesonide + Formoterol, Salbutamol, Budesonide |
Farmanguinhos |
Chron Epigen |
2012 |
Failure to comply with the requirements and constraints set out in the signed Commitment Term and the regulations in force during the extinction period. |
Nº 07/2012 |
2015 |
Ritonavir (Soft capsule) |
LAFEPE |
Cristália Produtos Químicos Farmacêuticos Ltda. |
2012 |
Public Institution reported, through Letter, the withdrawal of the PDP project, because Ritonavir presents lower storage and transport costs and for internalization it would be necessary high investment to adapt the manufacturing area to the need of equipment acquisition. |
Nº 08/2012 |
2017 |
Entacapone |
FURP, Lifal, IQUEGO |
EMS S.A. Nortec |
2012 |
Impossibility to centralize the purchase of this medicine at the time of the evaluation of the committee. |
Nº 11/2012 |
2017 |
Tolcapone |
Lifal |
Cristália Produtos Químicos Farmacêuticos Ltda. |
2012 |
Non-absorption of technology by the Public Institution, low added value of the product and non-centralized acquisition by the Ministry of Health, considering also that there are other therapeutic options available in the market. |
Nº 17/2012 |
2017 |
Selegiline |
Lifal |
Cristália Produtos Químicos Farmacêuticos Ltda. |
2012 |
Non-absorption of technology by the Public Institution, low added value of the product and non-centralized acquisition by the Ministry of Health, considering also that there are other therapeutic options available in the market. |
Nº 19/2012 |
2014 |
Docetaxel |
Farmanguinhos |
Libbs, Quiral |
2012 |
Failure to comply with the requirements and constraints set out in the signed Commitment Term and the regulations in force during the extinction period. |
Nº 03/2013 |
2015 |
Chloroquine phosphate |
LAFERGS |
Cristália Produtos Químicos Farmacêuticos Ltda. |
2013 |
The Public Institution did not have a manufacturing plant (needed investments in the production line) and the existence of chloroquine production in two other public institutions. |
Nº 08/2013 |
2018 |
Hearing aid |
FURP |
Politec Importações e Comércio Ltda |
2013 |
Non-evolution of the process of transfer and absorption of product technology; Manifestation of the public institution regarding the lack of interest of the private partner for the continuity of the PDP; Manifestation by Conjur/MS regarding the impracticability of direct acquisition of the product in the forms presented for this PDP. |
Nº 11/2013 |
2015 |
Cetuximab |
IVB, Bio-Manguinhos |
Bionovis, Merck Serono |
2013 |
The product was not incorporated by Conitec for the treatment of metastatic colorectal cancer. |
Nº 12/2013 |
2015 |
Cetuximab |
Butantan |
Libbs, Mabxience |
2013 |
The product was not incorporated by Conitec for the treatment of metastatic colorectal cancer. |
Nº 29/2013 |
2017 |
Allergenic Extracts |
Bahiafarma |
BioCen |
2013 |
Impossibility to centralize the purchase of this drug at the time of the evaluation of the committee. |
- |
2016 |
Docetaxel |
Farmanguinhos, LAQFA |
Cristália Produtos Químicos Farmacêuticos Ltda, Quiral Química do Brasil S.A. |
2015 |
It is impossible to centralize the purchase of this medicine. |
Nº 10/2018 |
2018 |
Simeprevir |
Farmanguinhos |
Blanver Farmoquímica e Farmacêutica S.A., Microbiológica Química e Farmacêutica Ltda. |
2018 |
The Health Surveillance Secretariat (SVS) reported that there are no expectations that Simeprevir will be presented as a therapeutic option in the next Clinical Protocol and Therapeutic Guidelines (PCDT). |